Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1958 1
1964 1
1966 1
1967 1
1968 11
1969 4
1971 1
1972 1
1973 1
1974 1
1975 1
1976 2
1977 3
1978 3
1980 1
1981 5
1982 7
1983 3
1984 3
1985 5
1986 4
1987 2
1988 16
1989 8
1990 13
1991 5
1992 10
1993 13
1994 8
1995 7
1996 7
1997 6
1998 13
1999 6
2000 7
2001 11
2002 8
2003 9
2004 8
2005 17
2006 13
2007 13
2008 17
2009 16
2010 29
2011 22
2012 25
2013 26
2014 27
2015 21
2016 29
2017 24
2018 19
2019 41
2020 53
2021 52
2022 43
2023 33
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

682 results

Results by year

Filters applied: . Clear all
Page 1
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, Marx N, Brosius FC 3rd, Mustafa RA, Agarwal A, Zou X, Mao Y, Asadollahifar A, Chowdhury SR, Zhai C, Gupta S, Gao Y, Lima JP, Numata K, Qiao Z, Fan Q, Yang Q, Jin Y, Ge L, Yang Q, Zhu H, Yang F, Chen Z, Lu X, He S, Chen X, Lyu X, An X, Chen Y, Hao Q, Standl E, Siemieniuk R, Agoritsas T, Tian H, Li S. Shi Q, et al. Among authors: numata k. BMJ. 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068. BMJ. 2023. PMID: 37024129 Free PMC article.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Among authors: numata k. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Kudo M, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaika M, Wisniewski T, Sangro B. Kudo M, et al. Among authors: numata k. J Hepatol. 2021 Sep;75(3):600-609. doi: 10.1016/j.jhep.2021.04.047. Epub 2021 May 26. J Hepatol. 2021. PMID: 34051329 Free article.
Complexity of Spider Dragline Silk.
Malay AD, Craig HC, Chen J, Oktaviani NA, Numata K. Malay AD, et al. Among authors: numata k. Biomacromolecules. 2022 May 9;23(5):1827-1840. doi: 10.1021/acs.biomac.1c01682. Epub 2022 Apr 4. Biomacromolecules. 2022. PMID: 35378031 Free PMC article. Review.
Cell Wall-Denaturing Molecules for Plant Gene Modification.
Naka R, Tsuchiya K, Numata K. Naka R, et al. Among authors: numata k. Chembiochem. 2023 Jun 15;24(12):e202200803. doi: 10.1002/cbic.202200803. Epub 2023 May 16. Chembiochem. 2023. PMID: 36811229 Review.
The Biomedical Use of Silk: Past, Present, Future.
Holland C, Numata K, Rnjak-Kovacina J, Seib FP. Holland C, et al. Among authors: numata k. Adv Healthc Mater. 2019 Jan;8(1):e1800465. doi: 10.1002/adhm.201800465. Epub 2018 Sep 20. Adv Healthc Mater. 2019. PMID: 30238637 Free article. Review.
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Fukushima T, Morimoto M, Kobayashi S, Ueno M, Uojima H, Hidaka H, Kusano C, Chuma M, Numata K, Tsuruya K, Arase Y, Kagawa T, Hattori N, Ikeda H, Watanabe T, Tanaka K, Maeda S. Fukushima T, et al. Among authors: numata k. Oncologist. 2023 Jul 5;28(7):e526-e533. doi: 10.1093/oncolo/oyad090. Oncologist. 2023. PMID: 37023703 Free PMC article.
682 results